Davis Polk advised Morgan Stanley & Co. LLC, Jefferies & Company, Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated as joint book-running managers in connection with the SEC-registered offering of 5,290,000 shares of common stock of Sagent Pharmaceuticals, Inc., of which 3,542,470 shares were sold by the Company and 1,747,530 shares were sold by certain selling shareholders. The amount sold by the selling shareholders included 690,000 shares from the full exercise of the underwriters’ option to purchase additional shares. The gross proceeds from the offering were approximately $70.7 million. Sagent Pharmaceuticals, Inc.’s common stock is traded on the NASDAQ Global Market under the symbol “SGNT.”

Based in Schaumberg, Illinois, Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.

The Davis Polk corporate team included partner John G. Crowley, associate Ryan G. Mitteness and law clerk Kate Darracott. The tax team included partner Kathleen L. Ferrell and former associate Kerry S. Price. The intellectual property team included associate Bruce Rose-Innes and law clerk Natalie A. Thomas. The environmental team included counsel Betty Moy Huber and associate Michael Comstock. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.